Amgen (AMGN) – Investment Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Amgen (NASDAQ: AMGN) in the last few weeks:

• 11/4/2026 – Amgen was given a new $440.00 price target by Canaccord Genuity Group.
• 11/4/2026 – Amgen was given a new $460.00 price target by Wells Fargo & Company.
• 11/4/2026 – Amgen had its “outperform” rating reaffirmed by William Blair.
• 11/4/2026 – Amgen had its price target raised by Cantor Fitzgerald from $440.00 to $465.00. They now have a “neutral” rating on the stock.
• 10/23/2026 – Amgen had its “outperform” rating reaffirmed by Oppenheimer.
• 10/23/2026 – Amgen had its price target raised by Oppenheimer from $450.00 to $480.00. They now have an “outperform” rating on the stock.
• 10/21/2026 – Amgen had its price target raised by Barclays from $380.00 to $400.00. They now have an “equal weight” rating on the stock.
• 10/18/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/13/2026 – Amgen had its price target lowered by Guggenheim from $388.00 to $378.00. They now have a “neutral” rating on the stock.
• 10/12/2026 – Amgen had its price target lowered by BMO Capital Markets from $450.00 to $415.00. They now have a “market perform” rating on the stock.
• 10/12/2026 – Amgen had its price target lowered by Wells Fargo & Company from $435.00 to $430.00. They now have an “equal weight” rating on the stock.
• 10/10/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/9/2026 – Amgen had its price target raised by UBS Group from $430.00 to $470.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Amgen was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 10/8/2026 – Amgen had its price target raised by Royal Bank Of Canada from $400.00 to $430.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Amgen had its price target raised by Truist Financial from $362.00 to $380.00. They now have a “hold” rating on the stock.
• 10/7/2026 – Amgen had its price target lowered by Morgan Stanley from $362.00 to $359.00. They now have an “equal weight” rating on the stock.
• 10/5/2026 – Amgen had its price target raised by Cantor Fitzgerald from $400.00 to $440.00. They now have a “neutral” rating on the stock.
• 9/28/2026 – Amgen had its price target raised by Scotiabank from $450.00 to $500.00. They now have an “outperform” rating on the stock.
• 9/23/2026 – Amgen had its “hold” rating reaffirmed by Jefferies Financial Group. They now have a $410.00 price target on the stock.
• 9/23/2026 – Amgen had its “outperform” rating reaffirmed by Oppenheimer.
• 9/17/2026 – Amgen had its “buy” rating reaffirmed by UBS Group. They now have a $430.00 price target on the stock.
• 9/10/2026 – Amgen was downgraded by HSBC from “buy” to “hold”. They now have a $425.00 price target on the stock, down from $445.00.
• 9/8/2026 – Amgen was downgraded by BMO Capital Markets from “outperform” to “market perform”. They now have a $450.00 price target on the stock.
• 9/8/2026 – Amgen had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $400.00 price target on the stock.

Amgen Stock Performance

Shares of AMGN opened at $461.26 on Wednesday. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The stock has a 50-day moving average of $420.83 and a two-hundred day moving average of $376.16. The stock has a market cap of $249.37 billion, a P/E ratio of 28.67, a P/E/G ratio of 3.41 and a beta of 0.43. Amgen Inc. has a one year low of $294.48 and a one year high of $475.64.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. The firm had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.64 earnings per share. As a group, research analysts predict that Amgen Inc. will post 22.96 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is 62.65%.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by company insiders.

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.